Palliative and adjuvant chemotherapy in colorectal cancer

European Journal of Cancer

Volumn 37, Issue SUPPL. 7, 2001, Pages

  Rougier, Philippe ^a  

^a HÔPITAL AMBROISE PARÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; COLORECTAL TUMOR; HUMAN; METHODOLOGY; PALLIATIVE THERAPY; PROGNOSIS; REVIEW;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; PALLIATIVE CARE; PROGNOSIS;

EID: 0035495504     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)80020-4     Document Type: Article

References (100)

1. Levi F, Lucchini F, La Vecchia C, Negri E. Trends in mortality from cancer in the European Union 1955-1994. Lancet 1999, 354: 742-743.
2. Faivre J, Rat P, Arveux P. Epidemiologie des metastases hepatiques des cancers des colon. In: Nordlinger B, Jaeck D (Eds.), Traitements des metastases hepatiques des cancers colorectaux. Springer-Verlag, Paris, 1992, pp 2-9.
3. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomised trial. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. J Clin Oncol 1992, 10: 904-911.
4. Scheithauer W, Rosen H, Kornek GV et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993, 306: 752-755.
5. Allen Mersh TG, Earlam S, Fordy C et al. Quality of life and survival with continuous hepatic artery infusion for colorectal liver metastases. Lancet 1994, 344: 1255-1260.
6. Moertel CG, Fleming TR, McDonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Eng J Med 1990, 322: 352-358.
7. Moertel CG, Fleming TR, McDonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of Stage III colon carcinoma: a final report. Ann Intern Med 1995, 122: 321-326.
8. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995, 345: 939-944.
9. O'Connell MJ, Maillaird JA, Kahn MJ et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15: 246-250.
10. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response. J Clin Oncol 1992, 10: 896-903.
11. Advanced Colorectal Cancer Meta-analysis Project. Metaanalysis of randomised trials testing the biochemical modulation of fluorouracil by methotrexate. J Clin Oncol 1994, 12: 960-969.
12. Piedbois P. The Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal carcinoma. J Clin Oncol 1998, 16: 301-308.
13. De Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997, 15: 808-815.
14. Kohne CH, Schoffski P, Wilke H et al. Effective biomodulation by leucovorin of high dose infusion fluorouracil given as a weekly 24-hour infusion: results of a randomized trial in patients with advanced colorectal cancer. J Clin Oncol 1998, 16: 418-426.
15. Schmoll HJ, Kohne CH, Lorenz M et al. Weekly 24h high-dose (HD) 5-fluorouracil (5-FU) with or without folinic acid (FA) vs. bolus 5-FU-FA (NCCTG/Mayo) in advanced colorectal cancer (CRC): Randomized phase III study of the EORTC, GITCCG and the AIO. Proc Am Soc Clin Oncol 2000, 19: 241a (Abstract #935).
16. Aranda E, Diaz-Rubio E, Cervantes A et al. Randomised trial comparing monthly low-dose leucovorin with weekly high-dose leucovorin and fluorouracil bolus with weekly high-dose 48hour continuous infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). Ann Oncol 1998, 9: 727-731.
17. Labianca R. First-line chemotherapy for advanced colorectal cancer: a significant step forward. Prog Colorectal Cancer 2000, 4: 1-2.
18. Aschele C, Gugliemi A, Frassineti GL et al. Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study. Br J Cancer 1998, 77: 341-346.
19. Giachetti S, Perpoint B, Zidani R et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18: 136-147.
20. Gamelin E, Boisdon-Celle M, Delva R et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentre prospective trial of fluorouracil dosage optimisation by pharmacokinetic monitoring in 152 patients. J Clin Oncol 1998, 16: 1470-1478.
21. Thirion P, Cassano A, O'Dwyer PJ, Weinerman B, Greco FA, Kohne CH et al. Meta-analysis of alpha-interferon plus 5-fluorouracil in advanced colorectal cancer. Proc Am Soc Clin Oncol 2000, 19: 244a.
22. Twelves C, Harper P, Van Cutsem E et al. A phase III trial (SO14796) of Xeloda (Capecitabine) in previously untreated advanced/metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999, 18: 263a.
23. Hoff PM, Ansari R, Batist G, Cox JV, Kocha W, Kuperminc M, Maroun J et al. Comparison of oral Capecitabine versus intravenous fluorouracil plus leucovorin as first line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001, 19: 2282-2292.
24. Pazdur R, Douillard J-Y, Skillings JR et al. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999, 18: 263a.
25. Carmichael J, Popiela T, Radstone S et al. Randomized comparative study of ORZEL (oral uracil/tegafur (UFT) plus leucovorin (LV)) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 1999, 18: 264a.
26. Wiseman LR, Markham A. Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996, 52: 606-623.
27. Raymond E, Chaney S, Taama A et al. Preclinical and clinical studies of oxaliplatin. Ann Oncol 1998, 9: 1053-1071.
28. Cunningham D, Pyrhonen S, James RD et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet 1998, 352: 1413-1418.
29. Rougier P, van Cutsem E, Bajetta E et al. Phase III trial of irinotecan versus infusional fluorouracil in patients with metastatic colorectal cancer after fluorouracil failure. The Lancet 1998, 352: 1407-1412.
30. Iveson TJ, Hickish T, Schmitt C, Van Cutsem E. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost effect compared with infusional 5-FU. Eur J Cancer 1999, 35: 1796-1804.
31. Pitot HC, Wender DB, O'Connell MJ et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997, 15: 2910-2919.
32. Conti JA, Kemeny NE, Saltz LB et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996, 14: 709-715.
33. Rougier P, Bugat R, Douillard JY et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pre-treated with fluorouracil based chemotherapy. J Clin Oncol 1997, 15: 251-260.
34. Saltz LB, Kanowitz J, Kemeny N et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996, 14: 2959-2967.
35. Ducreux M, Ychou M, Seitz J-F et al. Irinotecan combined with bolus fluorouracil. Continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pre-treated metastatic colorectal cancer. J Clin Oncol 1999, 16: 2901-2908.
36. Vanhoefer U, Harstrick A, Kohne C-H et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999, 16: 907-913.
37. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355: 1041-1047.
38. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Eng J Med 2000, 343: 905-914.
39. Scheithauer W, Kornek GV, Raderer M et al. Combined irinotecan and oxaliplatin plus granulocyte colony stimulating factor in patients with advanced fluoropyrimidine/leucovorin pretreated colorectal cancer. J Clin Oncol 1999, 17: 902-906.
40. Seitz JF, Perrier H, Giovannini M et al. 5-Fluorouracil, high-dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. J Chemother 1998, 10: 258-265.
41. Scheithauer W, Kornek GV, Brugger S et al. Randomized phase II study of irinotecan plus mitomycin (MMC) versus oxaliplatin plus MMC in patients with advanced fluoropyrimidine/leucovorin pretreated colorectal cancer (ACC). Onkologie 1999, 22 (Suppl 1): 78.
42. Levi F, Perpoint B, Garufi C et al. Oxaliplatin activity against metastatic colorectal cancer: A phase II study of 5-day continuous infusion at circadian rhythm modulated rate. Eur J Cancer 1993, 29: 1280-1284.
43. Machover D, Diaz-Rubio E, De Gramont A et al. Two consecutive phase II studies of oxaliplatin for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7: 95-98.
44. Becouarn Y, Ychou M, Ducreux M et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. J Clin Oncol 1998, 16: 2739-2744.
45. Levi F, Zidani R, Misset JL. Randomised mutlicentre trial of chronotherapy with oxaliplatin fluorouracil and folinic acid in metastatic colorectal cancer. International Organisation for Cancer Chronotherapy. Lancet 1997, 350: 681-686.
46. De Gramont A, Figer A, Seymour M et al. Leucovorin fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18: 2938-2947.
47. Figer A, Louvet C, Homerin M, Hmissi, Seymour M, Cassidy J et al. Analysis of prognostic factors of overall survival (OS) in the randomized trial of bimonthly leucovorin and 5-Fluorouracil regimen (LV5FU2) with or without owaliplatin (OXA) in advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1999, 18: 239a (Abstract #916).
48. Van Cutsem E, Szanto J, Roth A, Humblet Y, Köhne CH, Wils J et al. Evaluation of the addition of oxaliplatin (OXA) to the same Mayo or German 5FU regimen in advanced refractory colorectal cancer (ARCRC). Proc Am Soc Clin One 1999, 18: 234a (Abstract #900).
49. Maindrault-Goebel F, de Gramont A, Louvet C et al. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOL-FOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOD). Annal Oncol 2000, 11: 1477-1483.
50. Brienza S, Bensmaine MA, Soulie P et al. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate use program. Annal Oncol 1999, 10: 1311-1316.
51. Gil-Delgado M, Bastian G, Guinet G et al. Dose escalation of oxaliplatin (LOHP) + irinotecan (CPTII) and FU-FOL combination based on oxaliplatin pharmacokinetic (PK) analysis in advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2000, 19: 227a (Abstract #889).
52. Kemeny N, Tong W, Stockman J et al. Phase I trial of weekly oxaliplatin and irinotecan in previously treated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000, 19: 245a (Abstract #948).
53. Yves B, Mousseau M, Gamelin E et al. Final results of CPT-11 and L-OHP combination versus alternated combination of LV5FU2+ CPT-11/LV5FU2+ LOHP in 5FU-resistant advanced colorectal cancer. Proc Am Soc Clin Oncol 2000, 19: 252a (Abstract #978).
54. Falcone A, Masi G, Pfanner E et al. Phase I-II study of irinotecan (CPT-11), oxaliplatin (LOHP), leucovorin (LV) and 5-fluorouracil (5-FU) 48 hours continuous infusion (C.I.) in metastatic colorectal cancer patients. Proc Am Soc Clin Oncol 2000, 19: 297a (Abstract #1161).
55. Rougier P, Lepille D, Douillard JY et al. Final results of a randomised phase II study of three combinations: CPT-11 + LV5FU2, LOHP + LV5FU2 and CPT-11 + LOHP in 5-FU resistant advanced colorectal cancer (ACRC). Proc Am Soc Clin Oncol 2001, 20: 142a (Abstract #566).
56. Thirion P, Wolmark N, Haddad E et al. Survival impact of chemotherapy for patients with colorectal metastases confined to the liver. Annals Oncol 2000, 11: 1317-1320.
57. Kemeny N, Huang Y, Cohen AM. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases. N Eng J Med 1999, 341: 2039-2048.
58. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992, 10(7), 1112-1118.
59. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996, 88: 252-258.
60. Piedbois P, Bugat R, Ganem G et al. Intravenous 5FU/LV + CPT-11 combined with hepatic arterial infusion Pirarubicin in on resectable liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 2000, 19: 271a (Abstract #1056).
61. Paty P, Kemeny N, Tong W et al. A phase I/II study of hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone (DEX) with systemic irinotecan (CPT-11) for unresectable hepatic metastases from colorectal cancer. Proc Am Soc Clin Oncol 2000, 19: 260a (Abstract #1009).
62. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998, 24 (Suppl 2): 40-46.
63. Haller DG, Catalane PJ, Macdonald JS et al. Fluorouracil (FU), leucovorin (LEV) adjuvant therapy for colon cancer: four-year results of INT-0089. Proc Am Soc Clin Oncol 1997, 16: 265a.
64. O'Connell M.I, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998, 16: 295-300.
65. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, levamisole in patients with Dukes' B and C carcinoma of the colon: results from the National surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17: 3553-3559.
66. Quasar Collaborative Group. Comparison of fluoruracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. Lancet 2000, 355: 1588-1596.
67. Andre T, Colin P, Louvet C et al. Toxicity report of a Phase III trial (GERCOR C 96.1) comparing bimonthly LV5FU2 to monthly 5FU-Leucovorin high- dose (LV HD) in patients with Dukes' B and C colon cancer. Proc Am Soc Clin Oncol 2000, 19: 256a (Abstract #996).
68. Saini A, Cunningham D, Norman AR et al. Multicentre randomized trial of protracted venous infusion 5FU to 5FU/Folinic acid as adjuvant therapy for colorectal cancer. Proc Am Soc Clin Oncol 2000, 19: 240a (Abstract #928).
69. Poplin E, Benedetti J, Estes N et al. Phase III randomized trial of bolus 5FU/leucovorin/Levamisole versus 5FU continuous infusion/Levamisole or adjuvant therapy for high risk colon cancer (SWOG 9415/INT 0153). Proc Am Soc Clin oncol 2000, 19: 240a.
70. International Multicentre pooled analysis of B2 colon cancer trials (IMPACT B2). Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999, 17: 1356-1363.
71. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, C-04). J Clin Oncol 1999, 17: 1349-1355.
72. Seitz JF, Rougier P. Efficacité de la chimiothérapie dans les cancers du colon. Bull Cancer (Paris) 1994, 81: 260-76.
73. Sugarbaker PH, Gianola FJ, Speyer JL et al. Prospective randomized trial of intravenous versus intraperitoneal 5 FU in patients with advanced primary colon or rectal cancer. Semin Oncol 1985, 12: 101-111.
74. Vaillant JC, Nordlinger B, Deuffils et al. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer. A randomized trial. Ann Surg 2000, 231: 449-456.
75. Scheithauer W, Kornek G, Rosen H et al. Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma. Eur J Cancer 1995, 31A(12), 1981-1986.
76. Scheithauer W, Marczell A, Depisch D et al. Combined intravenous (IV) and intraperitoneal (IP) chemotherapy with 5-fluorouracil (5-FU) + leucovorin (LV) versus 5-FU + levamisole for adjuvant therapy of resected colon carcinoma. Proc Am Soc Clin Oncol 1996, 15: 216.
77. Taylor I, Machin D, Mullee M et al. A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer. Br J Surg 1985, 72(5), 359-363.
78. SAKK. Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK). Lancet 1995, 345: 349-353.
79. Wolmark N, Rockette H, Petrelli N et al. Long-term results of the efficacy of perioperative portal vein infusion of 5-FU for treatment of colon cancer: NSABP C-02. Proc Am Soc Clin Oncol 1994, 13: 194 (Abstract).
80. James R, AXIS collaborators. Intraportal 5FU (PVI) and peri-operativc radiotherapy (RT) in the adjuvant treatment of colorectal cancer (CRCa)-3681 patients randomized in the UK Coordinating Committee on Cancer Research (UKCCCR) AXIS trial. Proc Am Soc Clin Oncol 1999, 18: 264a (Abstract #1013).
81. Rougier P, Sahmoud T, Nitti D et al. Adjuvant portal vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. Lancet 1998, 351: 1677-1681.
82. Liver infusion meta-analysis group. Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst 1997, 89(7), 497-505.
83. Labianca R, Boffi L, Marsoni S et al. A randomized trial of intraportal (IP) versus systemic (SY) versus IP + SY adjuvant chemotherapy in patients with resected Dukes B-C colon carcinoma. Proc Am Soc Clin Oncol 1999, 18: 264a (Abstract #1014).
84. Paradiso A, Simone G, Petroni S et al. Thymidylate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 2000, 82: 560-567.
85. Sobrero A, Kerr D, Glimelius B et al. New directions in the treatment of colorectal cancer: a look to the future. Eur J Cancer 2000, 36: 559-566.
86. Kim R, Ohi Y, Inoue H, Toge T. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in oesophageal, gastric and colon cancers. Anticancer Res 1999, 19: 5393-5398.
87. Danenberg K, Salonga J, Park J et al. Dihydropyrimidine dehydrogenase and thymidylate synthase gene expression identify a high percentage of colorectal tumours responding to FU. Proc Am Soc Clin Oncol 1998, 17: (Abstract #992).
88. Iyer L, Janisch L, Das S et al. UGT1A1 promoter genotype correlates with pharmacokinetics of irinotecan CPT-11). Proc Am Soc Clin Oncol 2000, 19: 178a (Abstract #690).
89. Stevensen J, Redlinger M, Kluijtmans et al. Polymorphisms in the methylene tetrahydrofolate reductase (MTHFR) gene and toxicity produced by the thymidylate synthase inhibitor tomudex in a phase I clinical trial. Proc Am Soc Clin Oncol 2000, 19: 179a (Abstract #693).
90. Thebo JS, Sonagore AJ, Reinhold DS, Stapleton SR. Molecular staging of colorectal cancer: K-ras mutation analysis of lymph nodes upstages Dukes B patients. Dis Col Rectum 2000, 43: 155-159.
91. Sinicrope FA, Hart J, Hsu HA et al. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinoma. Clin Cancer Res 1999, 5: 1793-1804.
92. Elwell A, Xiong YP, Chang M et al. p53, p21 and thymidylate synthase (TS) protein expression: associations with recurrence in stage II and III rectal cancer. Proc Am Soc Clin Oncol 1997, 16: 258a (Abstract).
93. Shiota G, Ishida M, Noguchi N et al. Circulating p53 antibody in patients with colorectal cancer: relation to clinicopathologic features and survival. Dig Dis Sci 2000, 45: 122-128.
94. Hugh TJ, Dillon SA, Taylor BA et al. Cadherin-catenin expression in primary colorectal cancer: a survival analysis. Br J Cancer 1999, 80: 1046-1051.
95. Hugh TJ, Dillon SA, O'Dowd G et al. Beta-catenin expression in primary and metastatic colorectal carcinoma. Int J Cancer 1999, 82: 504-511.
96. Takahashi Y, Tucker SL, Kitadai Y et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node negative colon cancer. Arch Surg 1997, 132: 541-546.
97. Halling KC, French AJ, McDonnell SK et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999, 91: 1295-1303.
98. Gryfe R, Kim HK, Hsieh E et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000, 342: 69-77.
99. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B. Association of tumor site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 2000, 355: 1745-1750.
100. Tournigand C, Louvet C, Quinaux E et al. FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer (MCRC): final results of a phase III study. Proc Am Soc Clin Oncol 2001, 20: 124A (Abstract #494).